- Home
- BAFN vs HURA Comparison
BAFN vs HURA Comparison
Compare BAFN & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | BAFN | HURA |
|---|---|---|
| Founded | 1999 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.3M | 160.5M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | BAFN | HURA |
|---|---|---|
| Price | $6.85 | $1.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.04 |
| AVG Volume (30 Days) | 103.5K | ★ 230.8K |
| Earning Date | 10-29-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.93 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.26 | $0.41 |
| 52 Week High | $9.80 | $3.43 |
Technical Indicators
Market Signals| Indicator | BAFN | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 51.91 |
| Support Level | $5.98 | $1.83 |
| Resistance Level | $6.96 | $2.22 |
| Average True Range (ATR) | 0.62 | 0.13 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 58.04 | 57.14 |
Price Performance
Historical ComparisonAbout BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a bank holding company that operates through its wholly owned subsidiary. The Company generates the majority of its revenue from interest on loans and noninterest income. The primary sources of funding for its loans are loan payments, deposits, and borrowings. It is dependent on noninterest income, which is derived from net gain on the sales of the guaranteed portion of government-guaranteed loans and service fee income. The company provides personal banking and business banking services.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.